As cancer survivorship is increasing, cardiotoxicity is increasingly being recognised. Several cancer therapies can have a deleterious effect on cardiac function, some of which are reversible, some dose related and some irreversible. While this is a developing area, cardioprotective therapies have shown benefit especially if commenced early. Longer term benefits of cardioprotective therapy need to be determined.